Compare ESOA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | PEPG |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.4M | 207.1M |
| IPO Year | 2006 | 2022 |
| Metric | ESOA | PEPG |
|---|---|---|
| Price | $10.81 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $21.00 | $11.17 |
| AVG Volume (30 Days) | 114.8K | ★ 639.6K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $122,465,826.00 | N/A |
| Revenue This Year | $9.22 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $31.09 | ★ N/A |
| Revenue Growth | ★ 2.74 | N/A |
| 52 Week Low | $7.84 | $1.31 |
| 52 Week High | $19.94 | $7.80 |
| Indicator | ESOA | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 29.65 | 49.27 |
| Support Level | $8.62 | $1.60 |
| Resistance Level | $12.15 | $3.14 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 6.19 | 10.16 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.